🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

With routine care, half of patients with compensated MASH cirrhosis & obesity develop major adverse outcomes (MALO—such as liver failure, cancer, transplant, death) in 15 yrs. 🔥Bariatric surgery reduces that risk by 72%. nature.com/articles/s4159… #DDW2025 #EASL2025 #EASLCongress

Join us TODAY at Digestive Disease Week AASLD #Cirrhosis in the Obese Patient | 4–5:30PM PT | Room 6F Explore how #obesity and metabolic dysfunction reshape cirrhosis phenotypes and mgmt With Sobia Laique @QasimKhanMD + SOA by THE Kymberly Watt and a great list of abstract ppts

🔥session alert at #DDW2025 | AASLD Update on MASLD Therapies Pipeline From GLP-1s & SGLT-2i in cirrhosis to resmetirom eligibility& new phase 2 data on Efimosfermin (FGF-21 analogue) in MASH w/ fibrosis. Real-world insights + emerging data you don’t want to miss. #MASH

At EASL, sharing pathology insights with our hepatology community. Tons of learning all around. EASLnews

Mazen Noureddin, MD, MHSc presenting the most important data at the EASLnews #ILC2025 meeting. Reversal of cirrhosis is possible!! Amazing data. Pinnacle Clinical Research Pierre Gholam Arizona Liver Health North Shore Gastro Northeast Ohio Liver Alliance Alina Allen FattyLiverAlliance

Why does tirzepatide have a more tolerable gastrointestinal side effect profile than semaglutide? 🤢 GIP agonism coupled with GLP1 receptor agonism decreases gastrointestinal side effects. 🤲 In a study of a long-acting GIP added to liraglutide attenuated GI side effect rates

New ACG Clinical Guideline: Malnutrition in Liver Disease Malnutrition affects up to 80% of cirrhotics—yet often overlooked. Early nutrition care = better outcomes Read full guideline : journals.lww.com/ajg/fulltext/2… ACG

🆙 GLP1 discontinuation after one year is high Treatment discontinuation rate varies by study but can be 50% after 1 year. 👨‍🦳 🤢 Age >65 and gastrointestinal events are predictors of higher discontinuation rates. Those with type 2 diabetes have lower discontinuation rates.

📢 It’s OVER. The “lean MASLD paradox”? Just bad measurement. ❎MASLD with overweight BMI weren’t healthier! We were using the wrong metric. ↗️Waist circumference-related indices show a dose-dependent mortality risk across 3 prospective cohorts. Let’s reframe how we assess

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC JHEP Reports doi.org/10.1016/j.jhep… 👉FGF21 is central metabolic regulator 👉FGF21 negative prognostic marker 🧐We need biomarker to guide treatment in HCC ESMO - Eur. Oncology EASL Education ILCA

🚨NEW GLP1 RESEARCH: When GLP-1s stop, the weight comes back—fast. - - - A new Oxford meta-analysis (P04.009, EASO 2025) confirms what many clinicians have observed: stopping GLP-1 receptor agonists often leads to rapid and near-complete weight regain within 1–2 years. 📉 KEY

Obesity Drug Access: Who's Being Left Behind? - - - New data from JAMA (April 2025) reveals stark inequities in access to semaglutide (Wegovy) and tirzepatide (Zepbound) for obesity treatment. From 39 million patients without diabetes but eligible for treatment: 🔸Only 3%

Thank you ILTS for #ilts2025 YI award. Full work in Annals of Surgery Open offers improve liver graft utilization ONLY in high risk DBD and DCDs. Right now, OOS use no correlation with graft risk 😳. We define a better way forward. pubmed.ncbi.nlm.nih.gov/40255174/ 1/2

Excited to join Butts and Guts Cleveland Clinic to discuss the evolving #MASLD landscape—formerly known as fatty liver disease. We dive into updated nomenclature, diagnostic pathways, and emerging therapeutics shaping the future of care!

🧬 Breaking: Regeneron may have just improved upon basic GLP-1 weight loss therapy - - - New Phase 2 COURAGE trial top-line data suggest that combining semaglutide (Wegovy/Ozempic) with muscle-preserving antibodies could dramatically improve the quality of weight loss—not just

A first for #MASLD: The Cleveland Clinic MD MASLD Task Force brings together experts in #endocrinology, #metabolicsurgery, and #transplant to tackle MASH across the full disease spectrum. 💊 Emerging therapeutics 📍 Challenging cases 🧠 Expert panel debate Don’t miss this powerhouse